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           In response to microbial infection or tissue in-
jury, cells of the innate immune system, such as 
neutrophils, eosinophils, and basophils, mono-
cytes/macrophages, NK cells, and epithelial cells 
(including keratinocytes), produce antimicrobial 
peptides and proteins (AMPs), such as defensins, 
cathelicidins, and high mobility group box 1 
(HMGB1) proteins (  1  –  3  ). Recent studies have 
revealed that these AMPs, although structurally 
distinct, share some properties in addition to 
their direct antimicrobial eff  ect, including direct 
chemoattracting and activating activities for var-
ious subpopulations of leukocytes, including DCs 
in vitro, and the capacity to enhance antigen-
specifi  c immune responses to a coadministered 
antigen in vivo (  3, 4  ). These AMPs are rapidly 
released by leukocytes and/or various epithelial 
cells through cellular degranulation, necrosis, or 
immediate induction and secretion in response 
to danger signals, such as infection, tissue injury, 
and infl  ammatory cytokines. Based on their rapid 
release in response to infection or tissue injury, 
their dual roles as both chemoattractants and 
activators of antigen-presenting cells, as well as 
their capacity to enhance antigen-specifi  c im-
mune responses, we have classifi  ed these struc-
turally distinct AMPs as immune alarmins, which 
are defi  ned as endogenous mediators that rapidly 
galvanize host defenses against exogenous danger 
signals (  5, 6  ). 
  Eosinophil-derived neurotoxin (EDN), a 
member of the RNase A superfamily, is a me-
diator produced by human eosinophils and 
placental epithelial cells (  7  ). In addition to its 
ribonuclease activity (  7  ), EDN reduces the in-
fectivity of respiratory syncytial virus for target 
cells in vitro (  8  ) and is also responsible in part 
for the anti  –  HIV-1 activity found in the super-
natants of mixed lymphocyte cultures (  9  ), thus 
identifying EDN as an AMP. We have   previously 
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  Eosinophil-derived neurotoxin (EDN) is an eosinophil granule  –  derived secretory protein 
with ribonuclease and antiviral activity. We have previously shown that EDN can induce the 
migration and maturation of dendritic cells (DCs). Here, we report that EDN can activate 
myeloid DCs by triggering the Toll-like receptor (TLR)2  –  myeloid differentiation factor 88 
signaling pathway, thus establishing EDN as an endogenous ligand of TLR2. EDN activates 
TLR2 independently of TLR1 or TLR6. When mice were immunized with ovalbumin (OVA) 
together with EDN or with EDN-treated OVA-loaded DCs, EDN enhanced OVA-specifi  c T 
helper (Th)2-biased immune responses as indicated by predominant production of OVA-
specifi  c interleukin (IL)-5, IL-6, IL-10, and IL-13, as well as higher levels of immunoglobu-
lin (Ig)G1 than IgG2a. Based on its ability to serve as a chemoattractant and activator of 
DCs, as well as the capacity to enhance antigen-specifi  c immune responses, we consider 
EDN to have the properties of an endogenous alarmin that alerts the adaptive immune 
system for preferential enhancement of antigen-specifi  c Th2 immune responses. 2 of 12 EDN ACTIVATES DCS VIA TLR2 TO ENHANCE TH2 IMMUNE RESPONSE | Yang et al.
Of note, EDN at 2   μ  g/ml stimulated similar levels of IL-6, IL-8, 
and TNF-     , but much less IL-12p70 than 1   μ  g/ml of LPS 
(  Fig. 1 D  ). Furthermore, we also examined whether EDN-
treated DCs could migrate in response to an agonist for CCR5 
(regulated upon activation, normal T cell  –  expressed, and se-
creted [RANTES]) or CCR7 (secondary lymphoid tissue 
chemokine [SLC]). As expected, sham-treated DCs migrated 
in response to RANTES, but not SLC (  Fig. 1 E  , white bars), 
whereas LPS-treated DCs migrated in response to SLC, but 
not RANTES (  Fig. 1 E  , hatched bars). DCs incubated with 
1   μ  g/ml EDN for 24 h lost the capacity to migrate to RANTES, 
but gained the capacity to migrate to SLC, indicative of a 
switch in functional chemokine receptor expression from 
CCR5  +   to CCR7  +   (  Fig. 1 E  , solid bars). The ability of stromal 
cell  –  derived factor (SDF)-1      to induce the migration of all 
types of DCs provides a positive control and is in agreement 
with the reported expression of its receptor, CXCR4, by both 
immature and mature DCs (  14  ). Thus, EDN induced pheno-
typic maturation of DCs. 
  To ensure that EDN-induced maturation of DCs was 
refl  ected at the functional level, EDN-treated human DCs 
were analyzed for their capacity to stimulate the proliferation 
of T cells in an allogeneic mixed lymphocyte reaction using 
sham-treated DCs as a control (  Fig. 1 F  ). At the DC/T ratios 
tested (1:6,250~1:250), sham-treated DCs did not stimulate 
proliferation of allogeneic T cells as judged by the failure to 
increase [  3  H]  –  TdR incorporation. In contrast, DCs treated 
with 1   μ  g/ml EDN, similarly to LPS (1   μ  g/ml) -treated DCs, 
stimulated the proliferation of allogeneic T cells when used at 
a DC/T ratio higher than 1:6,250, indicating that EDN treat-
ment enhanced the capacity of DCs to stimulate T cell pro-
liferation. Thus, EDN treatment results in full activation of 
DCs that not only acquire a mature phenotype (  Fig. 1, C  –  E  ), 
but also become capable of antigen presentation and T cell 
stimulation (  Fig. 1 F  ). 
  EDN activates NF-     B and multiple mitogen-activated 
protein kinases (MAPKs) in DCs 
  Activation of DCs in response to many stimuli, such as cyto-
kines, CD40 ligand, and microbial products, converges in ac-
tivating intracellular signaling transducers, such as NF-     B and 
MAPKs (  15  –  18  ). To determine the eff  ect of EDN, the levels 
of I-     B      and MAPKs in DCs treated with EDN were deter-
mined by Western blot using   E. coli LPS   as a positive control 
(  Fig. 2  ).   LPS caused down-regulation of I-     B      and activation 
of JNK, p38, and Erk MAPKs with distinct kinetics (  Fig. 2  , 
right), similarly to previous reports (  17  –  19  ). EDN reduced 
the level of I-     B      in DCs in a time-dependent manner simi-
larly to LPS, which began to decrease after 5~10 min of treat-
ment and became evident after 20 min of treatment, indicating 
the activation of NF-     B by EDN (  Fig. 2  , left). EDN treat-
ment also activated all three MAPKs, including JNK, p38, 
and Erks, as shown by an increase in the levels of phosphory-
lated JNK, p38, and Erks (  Fig. 2  , left). Of note, EDN-in-
duced activation of DC MAPKs showed diff  erent kinetics 
from those induced by LPS. EDN-induced phosphorylation of 
shown that both EDN and mouse eosinophil  –  associated 
RNase 2, one of a cluster of divergent orthologs of human 
EDN, act as selective chemoattractants for DCs (  10  ). We have 
also reported that EDN has the ability to stimulate human 
DCs to produce a variety of proinfl  ammatory cytokines and 
to undergo phenotypic maturation (  11  ). In addition to its re-
lease by degranulation of eosinophils (  7, 12  ), EDN expression 
can also be induced in macrophages by treatment with TNF-      
and   Escherichia coli   LPS (  11  ). 
  In this study, we sought to investigate the mechanism of 
EDN-induced maturation of DCs and its capacity to enhance 
antigen-specifi  c immune responses in vivo. We have established 
that EDN can fully activate DCs in a myeloid diff  erentiation 
factor 88 (MyD88)- and Toll-like receptor (TLR)2-dependent 
manner, and demonstrated the capacity of EDN to enhance 
antigen-specifi  c Th2-polarized immune responses in vivo. Con-
sequently, our results demonstrate that EDN has the properties 
of an alarmin. 
    RESULTS   
  EDN induces full activation of DCs 
  DC activation is characterized by the development of a mature 
phenotype (including increased expression of surface costimu-
latory and MHC molecules, production of proinfl  ammatory 
cytokines, and conversion to a CCR7  +   phenotype) and the 
acquisition of the capacity for antigen presentation (  13, 14  ). 
We have previously reported that EDN, either purifi  ed from 
a natural source or recombinant, has the same capacity to up-
regulate CD80, CD83, and CD86 expression and production 
of a variety of cytokines by DCs (  11  ). To further determine its 
eff  ect on DCs, we performed a thorough analysis of the phe-
notype and function of human monocyte  –  derived DCs upon 
treatment with recombinant EDN. The recombinant EDN 
used in this study displayed a single band on SDS-PAGE gel 
(not depicted) and did not contain a detectable level of LPS or 
peptidoglycan (PGN) as measured by the Cambrex QCL-
1000 Chromogenic LAL Assay kit (  Fig. 1 A  ) and the Wako 
SLP Reagent Set (  Fig. 1 B  ), attesting to its purity.   The capacity 
of the same batch of EDN to induce DC IL-6 production was 
previously shown to be destroyed by boiling (  11  ). In addition, 
in comparison with EDN, human angiogenin (hAng) expressed 
in the same system did not induce DC IL-6 production (  11  ). 
Therefore, the eff  ect of EDN on DCs was unlikely to be due 
to LPS contamination. As shown by   Fig. 1 C  , human DCs 
incubated in the absence of any stimulant (sham-treated) for 
48 h were positive for CD11c (CD11c  +  ), negative for CD83 
(CD83        ), and expressed a very low level of CD80 (CD80  low  ) 
and an intermediate level of CD86 (CD86  int  ); these features 
are characteristic of an immature phenotype. DCs treated with 
EDN, similar to those treated with  E. coli   LPS, became CD83  +  , 
CD80  int  , and CD86  high  , characteristic of surface marker expres-
sion of mature DCs. Additionally, treatment of monocyte-
derived DCs with 200~2,000 ng/ml EDN for 48 h (  Fig. 1 D  , 
hatched bars) stimulated DC production of IL-6, IL-8, IL-
12p70, and TNF-      in a dose-dependent fashion as compared 
with DCs incubated without a stimulant (  Fig. 1 D  , open bars). JEM 
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    Figure 1.         EDN activation of DCs.   (A and B) Measurement of EDN preparation by the Wako SLP Reagent Set or Cambrex QCL-1000 Chromogenic LAL 
Assay kit for potential contamination with PGN and LPS, respectively. EDN preparation at the concentration tested (1~5   μ  g/ml) did not generate an opti-
cal density (O.D.) higher than that generated by the lowest concentration of standard PGN or LPS. (C) Flow cytometric analysis of the expression of DC 
surface markers. Monocyte-derived DCs were incubated in the absence (sham-treated) or presence of EDN at 1   μ  g/ml (EDN-treated) and LPS at 1   μ  g/ml 
(LPS-treated) for 48 h before immunostaining and fl  ow cytometric analysis. The position of quadrants was determined by DCs stained with FITC- and PE-
conjugated isotype-matched control antibodies. The density plots of the results of one of three representative experiments are shown. (D) Production of 
cytokines by DCs in response to EDN. Monocyte-derived iDCs (5   ×   10  5   cells/ml) were incubated in triplicate in the absence or presence of EDN and LPS at 
the specifi  ed concentrations for 48 h before the supernatant was harvested for the measurement of IL-6, IL-8, IL-12p70, and TNF-      levels by SearchLight 
microarray. The average (mean   ±   SD) of two experiments using independent donors is shown. *, P   <   0.05; **, P   <   0.001 when compared with the corre-
sponding sham-treated DC supernatant (open bars) using the unpaired   t   test. (E) Migration of EDN-treated DCs in response to selected chemokines. 
Monocyte-derived DCs were cultured in the absence (sham) or presence of 1   μ  g/ml EDN or LPS for 24 h before the measurement of their migration to the 
indicated chemokines using chemotaxis assay. RANTES, SLC, and SDF-1      were all used at 100 ng/ml. The migration of DCs is depicted as the average 
number of DCs per high-powered fi  eld (mean   ±   SD) of triplicate wells. (F) The proliferative response of human peripheral blood T lymphocytes to EDN-
treated allogeneic DCs. Monocyte-derived DCs were treated with or without (sham) 1   μ  g/ml EDN or LPS for 48 h at 37  °  C in humidifi  ed air with 5% CO  2  
for 48 h. Subsequently, the treated DCs were added together with T cells (10  5  /well) at the indicated DC/T ratio into 96-well plates and incubated at 37  °  C in 
humidifi  ed air with 5% CO  2   for 6 d with the addition of [  3  H]-TdR (0.5      Ci/well) for the last 18 h of incubation. The cells were harvested and measured for 
the incorporation of [  3  H]-TdR, illustrated as the average CPM (mean   ±   SD) of triplicate wells. *, P   <   0.05; **, P   <   0.001 when compared with the corre-
sponding sham group (unpaired   t   test).   4 of 12 EDN ACTIVATES DCS VIA TLR2 TO ENHANCE TH2 IMMUNE RESPONSE | Yang et al.
MyD88 plays a critical role in EDN-induced DC cytokine 
production (  Fig. 3 B  ). 
  EDN signals through TLR2 
  Among the many diverse DC-activating stimulants, only the 
IL-1 family of cytokines (including IL-18) and many TLR li-
gands activate DCs in a MyD88-dependent manner (  15, 21  ). 
There is no obvious structural or functional resemblance be-
tween EDN and cytokines. On the other hand, certain AMPs 
have previously been reported to act as endogenous TLR 
ligands, such as the activation of TLR4 by mouse      -defensin-2 
(  22  ) and of TLR2 and TLR4 by HMGB1 (  23, 24  ). Therefore, 
we investigated whether EDN could act as an endogenous 
  ligand for a TLR by determining if EDN could stimulate 
NF-     B activation in HEK293 cells transiently transfected with 
a combination of individual TLR and an NF-     B  –  reporting 
JNK only became evident after 20 min of incubation; however, 
LPS-induced JNK phosphorylation peaked at 5~10 min and 
began to decrease thereafter. In addition, EDN induced more 
rapid phosphorylation of DC Erks (peaked at 1 min) than LPS 
(peaked at 10 min). Furthermore, the ratio of phosphorylated 
p44/42/p38 in EDN-treated DCs was relatively higher than 
that of LPS-treated DCs (  Fig. 2  ). 
  EDN induction of IL-6 production by DCs requires MyD88 
  To identify the mechanism of EDN-induced DC activation, 
we applied the gripNA transient gene-silencing technique 
(  20  ) to investigate if blockade of MyD88 in human mono-
cyte  –  derived DCs would inhibit EDN-induced IL-6 produc-
tion. To this end, gripNA-hMyD88 was delivered into human 
monocyte  –  derived DCs, and the eff  ect of EDN or IL-1      on 
IL-6 production by the resulting DCs was measured. Com-
pared with DCs treated with Chariot II alone, DCs treated 
with Chariot II and gripNA  MyD88   produced much less IL-6 in 
response to EDN, suggesting that MyD88 might be involved 
in EDN-mediated DC activation (  Fig. 3 A  ).   IL-1       –  induced 
IL-6 production in DCs was partially (~37%) inhibited by 
gripNA  MyD88   treatment, suggesting incomplete blockade of 
DC MyD88 by gripNA  MyD88   transfection (  Fig. 3 A  ). To de-
termine whether MyD88 was required for EDN-induced DC 
activation, DCs derived from MyD88  +/+   and MyD88       /       
mice were used. When DCs generated from the bone marrow 
hematopoietic progenitor cells (HPCs) of littermate-matched 
MyD88  +/+   and MyD88       /       mice were tested for their capacity 
to produce IL-6 in response to EDN, EDN, like Pam3 and 
LPS, induced IL-6 production by MyD88  +/+   DCs, but failed 
to induce IL-6 production by MyD88       /       DCs, indicating that 
    Figure 2.         EDN induction of I-     B      degradation and phosphoryla-
tion of MAPKs in DCs.   Serum-starved DCs (4   ×   10  6   cells/tube in serum-
free RPMI 1640) were incubated at 37  °  C in the absence or presence of 
EDN or   E. coli   LPS  (fi  nal concentration, 1   μ  g/ml) for 30 min. EDN or LPS 
was added into corresponding tubes at the beginning and 10, 20, 25, and 
29 min of the incubation to ensure treatment for 30, 20, 10, 5, and 1 min, 
respectively. At the end of incubation, the cells were solubilized in SDS-
PAGE sample buffer. Identical amounts of cell lysate (15   μ  l) were run on a 
gradient SDS-PAGE gel and transferred onto a piece of PVDF membrane 
and sequentially Western blotted for I-    B    , phosphorylated JNK (p-JNK), 
p-p38, and p-Erks as described in the Materials and methods. Similar 
results were obtained in three independent experiments.     
    Figure 3.         EDN-induced IL-6 production was dependent on MyD88.  
(A) Human monocyte  –  derived DCs were transfected with or without 
(Chariot II alone) gripNAhMyD88. After 24 h of culture, the DCs (4   ×   10  5  
cells/ml) were incubated with EDN at the indicated concentrations for 40 
h, and the concentration of IL-6 in the culture supernatant was measured 
by ELISA. Shown are the data of one experiment representative of two. 
(B) DCs generated from the bone marrow progenitors of WT (MyD88  +/+ )  and 
MyD88 knockout (MyD88      /     ) mice were incubated at 10  6  /ml in the pres-
ence of 1   μ  g/ml Pam3, EDN, or LPS for 48 h, and the production of IL-6 
in the culture supernatants was measured by ELISA. The results of one 
experiment representative of two are presented as the average (mean   ±   SD) 
of triplicate wells.     JEM 
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a point mutation that renders TLR4 nonfunctional) mice 
(  Fig. 4 B  ). TLR2  +/+   DCs produced considerable levels of 
IL-6 in response to EDN, Pam3, and LPS. However, TLR2       /       
DCs failed to produce IL-6 in response to either EDN or 
Pam3, a known TLR2 ligand, but did produce IL-6 in re-
sponse to   E. coli   LPS, a TLR4 ligand. Additionally, EDN in-
duced a similar amount of IL-6 production by both C3H/HeN 
and C3H/HeJ DCs, suggesting that EDN does not trigger 
TLR4.   E. coli   LPS induction of similar levels of IL-6 from all 
but C3H/HeJ DCs ensured that C3H/HeJ DCs used in these 
experiments had no functional TLR4. These data clearly 
demonstrate that EDN is an endogenous ligand of TLR2. 
This conclusion is supported by the dependence of EDN-in-
duced DC IL-6 production on MyD88 (  Fig. 3  ) because 
MyD88 is the exclusive signal transducer for TLR2 (  15  ). 
Furthermore, the observation that EDN induced much less 
IL-12p70 than LPS (  Fig. 1 B  ) activated Erks MAPK more 
than p38 MAPK in DCs (  Fig. 2  ) is also consistent with the 
usage of TLR2 by EDN, as other TLR2 ligands have also 
been reported to have these properties (  19  ). 
  TLR2 often heterodimerizes with TLR1 or TLR6 to re-
spond to many TLR2 ligands (  21, 25  –  27  ). To determine 
whether EDN activation of DCs was also dependent on 
TLR1 or TLR6, we assessed whether EDN-induced produc-
tion of TNF-      and IL-6 by DCs derived from the bone mar-
row progenitors of TLR1       /      , TLR2       /      , TLR6       /      , and WT 
C57BL/6 mice using Pam3, a ligand for TLR2/1 (  25  ), fi  bro-
blast-stimulating lipopeptide (FSL)-1, a ligand for TLR2/6 
(  27  ), and   E. coli   LPS as controls (  Fig. 5  ).   As expected, LPS 
stimulated the production of similar amounts of TNF-      and 
IL-6 by all types of DCs. EDN, although capable of inducing 
comparable amounts of cytokines in WT, TLR1       /      , and 
luciferase construct. Human monocyte  –  derived DCs in our 
study expressed TLR1, 2, 3, 4, 5, 6, 7, 8, and 10 mRNAs, 
suggesting that TLR9 was unlikely to be involved (not 
depicted). In addition, the HEK293 cells used in our study, 
although expressing high levels of TLR5 and 6 mRNAs, 
and low levels of TLR1, 7, 8, and 10 mRNAs, did not show 
NF-     B activation in response to EDN (not depicted), sug-
gesting that EDN did not activate TLR1, 5, 6, 7, 8, and 10. 
When HEK293 cells transiently transfected with a NF-     B  –
  reporting luciferase construct together with plasmids express-
ing TLR2, TLR3, or a combination of TLR4 and MD-2 
were measured for the luciferase activity in response to EDN, 
EDN induced an increase in luciferase activity only in cells 
expressing TLR2, but not in those expressing either TLR3 
or TLR4, indicating that EDN interacted with TLR2 to acti-
vate NF-     B (  Fig. 4 A  ).   As expected, HEK293 cells expressing 
a particular TLR increased their luciferase activity in response 
to the corresponding agonists. 
  To confi  rm the requirement of TLR2 for EDN-induced 
activation of DCs, we compared EDN-induced production 
of IL-6 by DCs derived from the bone marrow progenitors of 
TLR2       /      , TLR2  +/+  , C3H/HeN, and C3H/HeJ (harboring 
    Figure 4.         EDN activates TLR2.   (A) HEK293 cells in a 96-well tissue 
culture plate were transfected with Ig     B-luciferase and pSV  –      -galactosi-
dase in the presence of human TLR2, TLR3, or TLR4 plus MD2. After over-
night culture, the cells were treated with of 20   μ  g/ml PGN, 10   μ  g/ml polyI:
C, 1   μ  g/ml LPS, or 1   μ  g/ml EDN for 24 h. The relative luciferase activity 
was measure and illustrated as the average RLU (mean   ±   SD) of triplicate 
wells. (B) DCs generated from the bone marrow progenitors of WT 
(TLR  +/+  ), TLR2 knockout (TLR      /     ), C3H/HeN, and C3H/HeJ mice were incu-
bated at 10  6  /ml in the presence of 1   μ  g/ml Pam3, EDN, or LPS for 48 h. 
The production of IL-6 in the culture supernatants was measured by ELISA 
and presented as the average (mean   ±   SD) of triplicate wells. The results 
of one experiment representative of three are shown.     
    Figure 5.         EDN induction of DC cytokine production does not 
depend on TLR1 or TLR6.   DCs were generated from the bone marrow 
HPCs of WT, TLR1      /    ,  TLR2     /     , and TLR6      /      C57BL/6 mice (10~12 wk old) 
as described in Materials and methods. Subsequently, DCs were plated at 
2   ×   10 5  /ml and treated in the absence (sham) or presence of 300 ng/ml 
Pam3, 1   μ  g/ml FSL-1, 1   μ  g/ml EDN, or 100 ng/ml   E. coli   (K12) LPS for 48 h 
at 37  °  C in humidifi  ed air with 5% CO  2   before the supernatants were har-
vested and assayed for TNF-      (top) and IL-6 (bottom) by ELISA. Similar 
results were obtained in two separate experiments.     6 of 12 EDN ACTIVATES DCS VIA TLR2 TO ENHANCE TH2 IMMUNE RESPONSE | Yang et al.
IgG1, but not IgG2 or IgG3, during the primary immune re-
sponse (  Fig. 6 C  ). During the secondary immune response, 
booster with OVA caused an enhancement of all subclasses of 
anti-OVA IgG antibodies in EDN-treated mice; however, the 
OVA-specifi  c IgG1 level was still higher than that of OVA-
specifi  c IgG2a, IgG2b, or IgG3 (  Fig. 6 D  ). Alum, as expected, 
promoted the generation of more anti-OVA IgG1 than IgG2a 
in both primary and secondary antibody responses (  Fig. 6, C 
and D  ). Because predominant generation of IgG1 antibody is 
an indicator of Th2 response, the data suggest that EDN may 
stimulate Th2 polarization. 
  To determine whether EDN enhancement of antigen-
specifi  c immune response depends on its capacity to activate 
TLR2 and to evaluate the nature of EDN-enhanced antigen-
specifi  c immune response, TLR2 knockout (TLR2       /      ) and 
littermate-matched control (TLR2  +/+  ) mice were immunized 
with OVA in the absence or presence of EDN or LPS, and 
the subsequent immune responses were measured. Spleno-
cytes from TLR2  +/+   mice immunized with OVA in the pres-
ence EDN or LPS incorporated signifi  cantly more [  3  H]-TdR 
than cells of mice immunized with OVA alone, indicating the 
enhancement of OVA-specifi  c T cell  –  proliferative response 
by EDN or LPS (  Fig. 7 A  ).   The splenocytes of TLR2  +/+   mice 
immunized with OVA in the presence of EDN produced 
predominantly IL-5, IL-6, IL-10, and IL-13, whereas spleno-
cytes of TLR2  +/+   mice immunized with OVA in the pres-
ence of LPS produced predominantly IFN-     , suggesting that 
EDN and LPS polarized in vivo OVA-specifi  c Th2 and Th1 
T cell responses, respectively (  Fig. 7 B  ). The production of 
OVA-specifi  c IL-4 was not signifi  cantly enhanced by simul-
taneous in vivo administration of either EDN or LPS (  Fig. 7 B  ). 
The anti-OVA IgG responses in TLR2  +/+   mice immunized 
with OVA in the presence of EDN were very similar to those 
in C57/BL6 mice (  Fig. 6  ), with signifi  cant enhancement of 
total anti-OVA IgG (  Fig. 7   C, a and b) and higher levels of 
IgG1 than IgG2a (  Fig. 7   C, c and d) in both primary (  Fig. 7   C, 
a and c) and secondary (  Fig. 7   C, b and d) antibody responses. 
TLR2  +/+   mice immunized with OVA in the presence of LPS 
also showed enhanced production of anti-OVA IgG (  Fig. 7   C, 
a and b); however, the predominant subclass was IgG2a 
(  Fig. 7   C, c and d), echoing the capacity of LPS to polarize 
Th1 immune response (  Fig. 7 B  ). Importantly, there was no 
enhancement of OVA-specifi  c T cell and antibody responses 
by EDN in TLR2       /       mice, whereas LPS similarly enhanced 
OVA-specifi  c T cell and antibody responses in both TLR2       /       
and TLR2  +/+   mice (  Fig. 7, A  –  C  ). Thus, the capacity of EDN 
to enhance antigen-specifi  c Th2-polarized immune response 
was dependent on TLR2. 
  EDN-activated DCs enhance antigen-specifi  c Th2 
immune response 
  To determine the role of DC activation in EDN enhance-
ment of antigen-specifi  c Th2 immune response, we investi-
gated whether OVA-loaded DCs that were activated by EDN 
in vitro could promote OVA-specifi  c Th2 immune response 
in vivo. To this end, DCs of WT or TLR2       /       mice were pulsed 
TLR6       /       DCs, did not induce TNF-      and IL-6 in TLR2       /       
DCs. The TLR1       /      , TLR2       /      , and TLR6       /       DCs showed the 
expected responses because (a) Pam3 and FSL-1 did not induce 
TNF-      and IL-6 production in TLR2       /       DCs, (b) Pam3 in-
duction of TNF-      was partially reduced in TLR1       /       DCs, 
and (c) FSL-1  –  induced TNF-      and IL-6 were greatly reduced 
in TLR6       /       DCs. These data demonstrate that EDN acts only 
on TLR2, not on a heterodimer of TLR2/1 or TLR2/6. 
  EDN enhances antigen-specifi  c Th2 immune response 
in a TLR2-dependent manner 
  To determine if EDN could enhance antigen-specifi  c immune 
responses, C57BL/6 mice were immunized with OVA in the 
absence or presence of EDN on day 1 and boosted on day 14 
with OVA alone. The levels of anti-OVA IgG antibody in the 
serum of mice taken on days 10 and 21 were measured for pri-
mary and secondary anti-OVA immune response. EDN dra-
matically enhanced both the primary (  Fig. 6 A  ) and secondary 
(  Fig. 6 B  ) anti-OVA antibody responses at both doses, demon-
strating the capacity of EDN to promote an antigen-specifi  c 
immune response.   Alum, as a positive control, also enhanced 
anti-OVA antibody responses as expected (  Fig. 6, A and B  ). 
hAng, another member of the RNase superfamily, which 
is unable to induce either migration or maturation of DCs 
(  10, 11  ), did not enhance the primary or secondary anti-OVA 
antibody responses (  Fig. 6, A and B  ). Assaying the subclass of 
anti-OVA IgG antibodies revealed that coimmunization with 
EDN selectively enhanced the production of OVA-specifi  c 
    Figure 6.         Enhancement of OVA-specifi  c immune responses by 
EDN.   C57BL/6 mice (female, 8-wk old,   n   = 10) were immunized by i.p. 
injection of 50   μ  g OVA in the presence or absence of alum (3 mg/mouse), 
EDN, or hAng on day 1 and boosted by i.p. injection of 50   μ  g OVA alone 
on day 14. Serum samples were taken on days 10 (A and C) and 21 (B and 
D) from each mouse for the measurement of total (A and B) and subclass 
(C and D) anti-OVA IgG antibodies using ELISA. The average OVA-specifi  c 
IgG antibody titers (mean   ±   SEM) of each group is shown. *, P   <   0.001 
compared with the group immunized with OVA alone (Mann-Whitney 
test). Similar results were obtained in three independent experiments.     JEM 
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with OVA, treated with EDN (or   E. coli   LPS as a control), 
and injected into the peritoneal cavity of C57BL/6 mice. 
The mice were immunized i.p. with OVA on day 5 and killed 
on day 12 for the determination of OVA-specifi  c splenocyte 
production of cytokines. WT DCs in response to EDN pro-
duced a substantial amount of IL-1     , IL-6, IL-10, and TNF-     , 
a low (nevertheless statistically signifi   cant) amount of IL-
12p70, and a little IL-23 (  Fig. 8 A  ).   LPS enhanced DC pro-
duction of all cytokines measured, with much less induction 
of IL-10 and much greater induction of IL-6, IL-12p70, and 
IL-23 in comparison with EDN treatment ( Fig. 8 A ). TLR2       /       
DCs did not produce any signifi  cant cytokine in response to 
EDN (  Fig. 8 A  ). The splenocytes of C57BL/6 mice immu-
nized with OVA-loaded and EDN-treated WT DCs gener-
ated predominantly IL-5, IL-6, IL-10, and IL-13, but no 
IFN-      when stimulated with OVA (  Fig. 8 B  ). In contrast, the 
splenocytes of mice immunized with LPS-treated DCs pre-
dominantly generated IFN-     , some IL-6 and IL-10, but no 
IL-5 or IL-13 upon OVA stimulation (  Fig. 8 B  ). The spleno-
cytes of mice immunized with EDN-treated TLR2       /       DCs 
did not produce any Th1 or Th2 cytokines (  Fig. 8 B  ). These 
data, in addition to further strengthening the conclusion that 
EDN activates DCs by triggering TLR2, also demonstrate 
that DCs contribute to EDN enhancement of OVA-specifi  c 
Th2 immune response. 
    DISCUSSION   
  It has been well established that TLRs can recognize infec-
tious   “  nonself  ”   by sensing pathogen-associated molecular 
patterns and triggering antimicrobial immune responses of the 
host (  28, 29  ); however, emerging evidence indicates that 
certain endogenous molecules can also activate TLRs. Several 
endogenous ligands have been reported to activate TLR4, 
such as fi  bronectin extra domain A (  30  ), fi  brinogen (  31  ), lung 
surfactant protein A (  32  ), heparan sulfate (  33  ), hyaluronan 
fragments (  34, 35  ), and mouse      -defensin-2 (  22  ). Mammalian 
RNA and DNA in the form of immune complexes can act as 
endogenous ligands for TLR7 and TLR9, respectively (  36, 37  ). 
Although heat shock proteins and HMGB1 have been re-
ported to trigger both TLR2 and TLR4 (  23, 24, 38  –  40  ), no 
endogenous ligand acting exclusively on TLR2 has been re-
ported previously. We have shown that EDN is capable of 
inducing DC maturation, cytokine production, and activation 
of NF-     B and multiple MAPKs in DCs (  Figs. 1 and 2  ). In ad-
dition, EDN induction of NF-     B activation in HEK293 cells 
is mediated by TLR2, and EDN-induced DC cytokine pro-
duction is abrogated in TLR2       /       DCs, but not in TLR1       /      , 
    Figure 7.         EDN enhancement of OVA-specifi  c Th2-biased immune 
responses is ablated in TLR2 knockout (TLR2    2  /  2   ) mice.   TLR2     /      and 
littermate-matched TLR2  +/+   mice (female, 8-wk old,   n   = 4) were immu-
nized by i.p. injection of 50   μ  g OVA in the presence or absence of EDN 
(1   μ  g/mouse) or LPS (1   μ  g/mouse) on day 1 and boosted by i.p. injection 
of 50   μ  g OVA alone on day 14. Serum samples were taken on days 10 and 20 
for the measurement of anti-OVA IgG antibodies using ELISA. On day 20, 
mice were killed and their spleens removed for the determination of 
OVA-specifi  c proliferation and cytokine production. (A) Pooled splenocytes 
(5   ×   10 5  /0.2 ml/well) were stimulated with OVA at concentrations speci-
fi  ed for 60 h with [  3  H]-TdR pulse (1      Ci/well) for the last 18 h. Splenocyte 
proliferation was shown as the average (mean   ±   SD) [  3 H]-TdR  incorpora-
tion (CPM) of triplicate wells of one experiment representative of two. 
*, P   <   0.001 by Student  ’  s   t   test. (B) Pooled splenocytes (5   ×   10  6  /1 ml/well) of 
each group were stimulated with 100   μ  g/ml OVA for 48 h, and the cyto-
kines in the supernatants were measured by multiplex ELISA. Shown are 
the averages (mean   ±   SD) of individual cytokines of two independent 
experiments. (C) The average (mean   ±   SEM) of OVA-specifi  c IgG antibody 
titers (a and b) and subclass (c and d) of each group (  n   = 4) on days 10 
(a and c) and 21 (b and d) are shown. *, P   <   0.001 by Mann-Whitney test. 
Similar results were obtained in two independent experiments.     
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data demonstrating that EDN, in comparison with   E. coli   LPS, 
induces much less IL-12p70 and considerably more IL-10 
production by both human and mouse DCs (  Figs. 1 D   and 
  8 B  ). Conventional Th2 T cells, such as those generated in 
response to   Schistosoma   infection or DCs conditioned with 
  Schistosoma mansoni   egg antigen treatment, are characterized 
by simultaneous production of IL-4, IL-5, IL-10, and IL-13 
(  41, 42  ). In contrast, OVA-specifi  c Th2 cells promoted by 
EDN diff  er from conventional Th2 cells in lacking production 
of IL-4 (  Figs. 7 B and 8 B  ). It has also been documented that 
thymic stromal lymphopoietin can also condition DCs for the 
induction of Th2 cells that are distinct from conventional Th2 
cells in producing IL-4, IL-5, IL-13, and TNF-     , but not 
IL-10 (  43, 44  ). It thus appears that diff  erent stimulants can induce 
the generation of Th2 with a distinct cytokine profi  le. It re-
mains to be determined why EDN leads to the generation of 
Th2 cells with this particular profi  le of cytokine production. 
  EDN stimulates DCs to generate an abundant amount of 
IL-6 and IL-1      (  Figs. 1 and 8  ), and eosinophil can produce 
TGF-      (  45  ). Because IL-6, IL-1     , and TGF-      are known 
to contribute to the diff  erentiation of CD4 T cells into Th17 
lineage (  46  ), it is conceivable that eosinophils and/or EDN 
may promote the generation of antigen-specifi  c Th17 cells. 
How  ever, the splenocytes of mice immunized with EDN 
and OVA did not produce a signifi  cant amount of IL-17 (not 
depicted). Therefore, EDN could not promote the genera-
tion of Th17 cells, at least in the mouse models used in the 
present study. 
  EDN uses the TLR2  –  MyD88 signal transduction pathway 
for the activation of DCs and enhances OVA-specifi  c Th2-
polarized immune responses in a TLR2-dependent manner. 
Our data are consistent with several previous reports showing 
that DCs activated by TLR2 agonists exhibit more pro-
nounced Erk activation, produce less IL-12p70, and preferen-
tially induce antigen-specifi  c Th2-polarized immune responses 
(  19, 47  –  49  ). Is MyD88 or TLR2 crucial for Th2 polarization? 
Ample evidence indicates that signaling through MyD88 does 
not determine Th1/Th2 polarization. For example, MyD88 is 
not required for   Schistosoma mansoni   egg antigen  –  induced Th2 
polarization (  50  ). Moreover, although both TLR2 and TLR9 
transduce signals exclusively through MyD88 (  21, 28, 29  ), 
their agonists, PGN and synthetic stimulatory oligodeoxy-
nucleotide, enhance Th2- and Th1-type immune responses, 
respectively (  48  ). The TLR2 ligands, such as Pam3, PGN, and 
EDN, upon coadministration with antigen in the primary 
immunization, promote distinct Th2-type antigen-specifi  c 
immune responses (  19, 47  –  49  , and this study), suggesting that 
signaling through TLR2 has the potential to promote Th2 
polarization under certain conditions. However, TLR2 ago-
nists, such as Pam3, lipoteichic acid, and macrophage-activating 
lipopeptide 2, are capable of suppressing previously estab-
lished allergic Th2 responses (  51  –  53  ).   Propionebacterium acnes  , 
albeit activating DCs via TLR2, not only induce a Pa-specifi  c 
Th1 immune response (  54  ), but also stimulate DCs to generate 
a negative signal for Th2 development in a MyD88-dependent 
manner (  55  ). Compared with most other TLR2 agonists, 
TLR4       /      , or TLR6       /       DCs (  Figs. 4, 5, and 8  ). Furthermore, 
EDN enhancement of OVA-specifi  c immune responses also 
relies on TLR2 (  Figs. 7 and 8  ). Thus, EDN appears to be a 
TLR2-specifi  c endogenous ligand with the capacity to enhance 
antigen-specifi  c immune responses. 
  EDN enhancement of OVA-specifi  c immune responses 
can be achieved by immunizing mice either with OVA in the 
presence of EDN (  Figs. 6 and 7  ) or with EDN-activated 
OVA-loaded DCs (  Fig. 8  ). The antigen-specifi  c immune re-
sponse selectively promoted by EDN is predominantly of the 
Th2 type, which is indicated by preferential promotion of 
antigen-specifi  c IgG1 production in both the primary and 
secondary antibody responses (  Figs. 6   and   7 C  ), as well as gen-
eration of T cells that are capable of secreting elevated levels 
of IL-5, IL-6, IL-10, and IL-13, but not of IFN-      or TNF-      
(  Figs. 7 B     and 8 B  ). This notion is in good agreement with 
    Figure 8.         DCs treated with EDN promote Th2 immune response.   DCs 
generated from the bone marrow progenitors of WT or TLR2 knockout mice 
were incubated with 100   μ  g/ml OVA for 24 h, and then cultured at 2   ×   10  5 /ml 
in the presence or absence of 1   μ  g/ml EDN or   E. coli   LPS for another 24 h. 
After harvesting supernatants for cytokine measurement, DCs were washed 
with PBS three times and suspended in PBS at 2.5   ×   10  6  /ml. C57BL/6 mice 
(three mice/group) were injected i.p. with 0.2 ml DC suspension on day 0, 
immunized i.p. with OVA (50   μ  g/0.2 ml PBS/mouse) on day 4, and killed 
on day 11 for the removal of spleens. Single splenocyte suspensions in 
complete RPMI 1640 were prepared from pooled spleens of each group 
and stimulated in vitro with 100   μ  g/ml OVA for 48 h for the measurement 
of OVA-specifi  c cytokine production by splenocytes. (A) The production of 
cytokines in the supernatants of differently treated DCs was shown as the 
average (mean   ±   SD) of two independent experiments. (B) The generation 
of OVA-specifi  c cytokines by splenocytes of various groups of mice was 
shown as the average (mean   ±   SD) of two independent experiments. 
*, P   <   0.05 compared with sham-treated group (Mann-Whitney test).     JEM 
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eight or more generations onto the C57BL/6 background, and then inter-
crossed to obtain the knockout genotypes. C57BL/6, C3H/HeN, and 
C3H/HeJ mice were obtained from Charles River Laboratories. All mice 
were kept under specifi  c pathogen-free conditions, with water and food 
given ad libitum. All experiments with mice were performed in compliance 
with the principles and procedures outlined in the NIH Guide for the Care 
and Use of Animals and were approved by the NCI-Frederick Animal Care 
and Use Committee. 
  Cell isolation and purifi  cation.     Human PBMCs were isolated by Ficoll 
density gradient centrifugation as described previously (  65  ). Monocytes were 
purifi  ed (  >  95%) from human PBMCs with MACS CD14 monocyte isola-
tion kit (Miltenyi Biotec). Human T cells were isolated from human PBMCs 
by using CD3 Enrichment Columns (R  &  D Systems). Mouse HPCs were 
isolated as reported previously (  66  ) from the bone marrow of knockout and 
littermate-matched WT mice. 
  DC generation and treatment.     Human and mouse DCs were gener-
ated as described previously (  66  ). In brief, monocytes or mouse bone mar-
row progenitors were incubated at 2~5   ×   10  5  /ml in G4 medium (RPMI 
1640 containing 10% FBS [Hyclone], 2 mM glutamine, 25 mM Hepes, 100 
U/ml penicillin, 100      g/ml streptomycin, 50 ng/ml of human or mouse 
GM-CSF, and 50 ng/ml of human or mouse IL-4) at 37  °  C in a CO  2   (5%) 
incubator for 5~7 d to generate immature DCs (iDCs), with 50% of the 
culture medium replaced with prewarmed fresh G4 medium on days 3 and 
5. Subsequently, iDCs were incubated in fresh G4 medium in the absence 
or presence of EDN, Pam3 (  N  -palmitoyl-S-[2,3-bis(palmitoyloxy)-(2RS)-
propyl]-[R]-cys-[S]-serl-[S]-lys [reference   4  ] trihydrochloride; InvivoGen), 
FSL-1 (InvivoGen), or LPS (  E. coli   O55:B5; Sigma-Aldrich) at specifi  ed 
concentrations for 24~48 h in a CO  2   (5%) incubator before analyzing their 
phenotype and function. In some experiments, mouse DCs were pulsed 
with antigen by incubating with 100   μ  g/ml OVA for 24 h before treatment 
with EDN or   E. coli   LPS. 
  For the transient silencing of DC MyD88, monocyte-derived iDCs 
were transduced without or with gripNA  MyD88   (5     -CCTGCAGCCAYDD-
CGGGC-3     ; Active Motif) at 10 nmol/10  6   cells using Chariot II (Active 
Motif) according to the manufacturer  ’  s instructions. After overnight incuba-
tion, both sham-transfected and gripNA  MyD88  -transfected DCs were harvested, 
counted, and treated with EDN or IL-1      for 24 h before the collection of 
the culture supernatants. 
  Measurement of DC phenotype and function.     Multiple cytokines in 
the culture supernatants of human DCs were measured using SearchLight 
microassay (Thermo Fisher Scientifi  c). Mouse IL-6 and TNF-      in the 
  supernatants of mouse DC culture were measured using ELISA kits (R  &  D 
Systems). DC migration was assessed using a 48-well microchemotaxis 
chamber assay, as described previously (  67  ). The expression of surface mole-
cules was determined by fl  ow cytometry using a FACScan (Becton Dickin-
son) after staining DCs (5   ×   10  5  /sample) with FITC- or PE-conjugated 
mouse monoclonal antibodies (all from BD Biosciences) against human 
CD11c (IgG1,      , clone B-Ly6), CD80 (IgG1,      , clone L307.4), CD83 
(IgG1,      , clone HB15e), CD86 (IgG1,      , clone 2331), or isotype-matched 
control antibodies. The capacity of DCs to stimulate the proliferation of 
allogeneic T cells was evaluated by mixed lymphocyte reaction (  68  ) with 
minor modifi  cations. In brief, purifi  ed allogeneic T cells (10  5  /well) were 
cultured with diff  erent numbers of DCs treated in the absence (sham) or 
presence of EDN in a 96-well fl  at-bottom plate for 6 d at 37  °  C in humidi-
fi  ed air with 5% CO  2  . The proliferative response of T cells was examined by 
pulsing the culture with 0.5   μ  Ci/well of [  3  H]-TdR (New England Nuclear) 
for the last 18 h before harvesting. [  3  H]-TdR incorporation was measured 
with a microbeta counter (Wallac). 
  Western blot.     DCs starved in serum-free G4 medium for 6 h were incu-
bated at 37  °  C in the absence or presence of 1   μ  g/ml EDN or LPS for a pe-
riod of time as specifi  ed. Treated cells were lysed in SDS sample buff  er (62.5 mM 
zymosan is reported to induce IL-10  –  producing antigen-specifi  c 
Tr1 without generation of either Th1 or Th2 T cells (  56  ). 
Thus, the eff  ect of TLR2 activation on the polarization of Th 
responses may be infl  uenced by multiple factors, such as the 
type of TLR2 ligands and the means and timing of administra-
tion, and it is still in need of further investigation. 
  The recruitment and activation of eosinophils are most 
often seen in tissues subject to parasitic infection and allergy 
(  7, 41, 57  ). EDN is likely to be generated and present at sites 
of infl  ammation associated with such disorders. EDN is pres-
ent in the serum and nasal lavage fl  uid of healthy individuals 
at ~20 ng/ml (  58, 59  ), but its concentration in the nasal lavage 
fl  uid of patients with allergic rhinitis can reach as high as 
880 ng/ml (  60  ), suggesting that EDN in tissues subject to 
allergic reaction or parasitic infection can reach a concentra-
tion (100~1,000 ng/ml) necessary for the activation of DCs 
and enhancement of immune response described in the present 
study. Therefore, the capacity of EDN to activate DCs and to 
enhance a Th2-polarized immune response may provide a 
basis for the induction and/or maintenance of a Th2-polarized 
immune response during parasitic infection, allergy, or atopic 
reaction. However, a recent report showing that there is no 
defi  cit in the generation of IL-4 and IL-5 in eosinophil-
ablated mice in response to helminth infection (  61  ) suggests 
that eosinophil, and consequently eosinophil-generated EDN, 
may not be required for the generation of Th2-type immune 
response. How can this report be reconciled with data of the 
present study? Because EDN can also be produced by cells other 
than eosinophils, such as neutrophils, macrophages, and certain 
placental epithelial cells (  7, 11, 62  ), it is possible for EDN to be 
present at sites of infection even in the absence of eosinophils. 
It is also possible that factors other than EDN provide the 
Th2-polarizing signal in the absence of eosinophils. 
  Alarmins are defi  ned as endogenous mediators rapidly re-
leased by cells of the host innate immune system in response 
to infection and/or tissue injury, which possess the dual ac-
tivities of recruiting and activating DCs and consequently are 
capable of enhancing antigen-specifi  c adaptive immune re-
sponses (  5, 6  ). EDN is an endogenous mediator rapidly 
released from eosinophils, neutrophils, and by activated mac-
rophages (  7, 11, 12, 62  ). In addition, EDN can selectively in-
duce the recruitment of DCs to the site of infl  ammation (  10  ). 
Furthermore, EDN has DC-activating activity and enhances 
antigen-specifi  c immune response in vivo (this study). Thus, 
EDN can be considered a bona fi  de alarmin that favors an 
  alternative type of Th2 immune response. 
  MATERIALS AND METHODS 
  Reagents and mice.     Recombinant human and mouse GM-CSF, IL-4, 
SDF-1     , RANTES, and SLC were purchased from PeproTech. Recombi-
nant EDN was generated and purifi  ed as described previously (  11  ). The 
purity of this batch of EDN was analyzed by SDS-PAGE. The potential 
levels of contaminating LPS and PGN in the sample were measured using 
QCL-1000 Chromogenic LAL Assay kit (Cambrex) and SLP Reagent Set 
(Wako) according to the manufacturers  ’   protocols. hAng was purchased 
from R  &  D Systems. 
  MyD88    –  /  –   , TLR1    –  /  –   , TLR2    –  /  –   , and TLR6    –  /  –    mice generated by S. 
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